EGFR and small cell lung carcinoma: Although EGFR tyrosine kinase inhibitors (EGFR-TKIs; such as gefitinib) are not effective in a SCLC clinical trial [37], the identification of a subgroup of patients with EGFR overexpression suggest an alternative approach by using EGFR antibody.